Raz Yirmiya

Yirmiya, R. The inflammatory underpinning of Depression – an historical perspective. Brain, Behavior and Immunity, 122: 433-443, 2024. [[Link]

Dinur et al., A Novel Anti-Inflammatory Formulation Comprising Celecoxib and Cannabidiol Exerts Antidepressant and Anxiolytic Effects. Cannabis and Cannabinoid Research, 2024. [Link]

Yirmiya R, Depressive disorder-associated microglia as a target for personalized antidepressant approach. Biological Psychiatry, Biological Psychiatry. 94: 602-604, 2023. [Link]

Naggan et al. Suicide in bipolar disorder patients is associated with hippocampal microglia activation and reduction of lymphocytes-activation gene 3 (LAG3) microglial checkpoint expression. Brain, Behavior and Immunity, 110: 185-194, 2023. [Link]

Goshen et al., Mentoring: A three-generation perspective. Neuron, 110: 363-365, 2022. [Link]

Rimmerman N, et al. Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effs of electroconvulsive stimulation. Molecular Psychiatry, 27: 1120–1135, 2022. [Link]

Yirmiya R and Kreisel T. Treatment of mood disorders and stress related disorders. US Granted patent number US9950036B2. April 24, 2018. [Link]

Yirmiya R. Treatment of mood disorders and stress related disorders (CIP). US Granted patent numbe US10626178B2. April 21, 2020. [Link]

Yirmiya R. Microglia modulators for use in treatment of depression. US Application number US2021/10077477A1. March 18, 2021. [Link]

Yirmiya R. Composition comprising cannabinoids, terpenes, and flavonoids for treating depression. US Application number US20230270764A1, July, 14, 2021. [Link]

More Publication

Raz Yirmiya

Laboratory for PsychoNeuroImmunology Research

Contact

Recent Publications